BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 7566929)

  • 1. [Use of taxol in the management of malignant tumors].
    Eckhardt S
    Orv Hetil; 1995 Sep; 136(37):1987-93. PubMed ID: 7566929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview.
    Hájek R; Vorlicek J; Slavik M
    Neoplasma; 1996; 43(3):141-54. PubMed ID: 8841500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-hour paclitaxel infusion schedules: a phase I/II comparative trial.
    Greco FA; Hainsworth JD
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):118-23. PubMed ID: 7597427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Taxol--a new cytostatic drug for therapy of ovarian and breast cancer].
    Meden H; Rath W; Kuhn W
    Geburtshilfe Frauenheilkd; 1994 Apr; 54(4):187-93. PubMed ID: 7912212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evidenced-based medicine and future direction of Taxol].
    Hatae M; Nakamura T; Ohnishi Y
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1279-87. PubMed ID: 10945027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Taxol (paclitaxel) as second-line therapy in breast and ovarian cancer].
    Borovik R; Steiner M; Atad J; Sneiderman B; Rosenberg T; Palti S
    Harefuah; 1998 Apr; 134(8):605-8, 671. PubMed ID: 10911422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Phase I study of paclitaxel].
    Horikoshi N; Inoue K; Aiba K; Mukaiyama T; Ogihara A; Sumida T; Akatsuka Y; Besho A; Inamoto Y; Uchida T
    Gan To Kagaku Ryoho; 1994 Oct; 21(14):2407-14. PubMed ID: 7944484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
    Ezcurdia L; Jovtis SL; Mickiewicz E; Temperley G; Rondinón M; Blajman C; Cóppola FS; Lewi D; Cazap E; Breier S; Fasce H; Fein L; Polera J; Triguboff E; Uranga G; Pasccón G; Luchina AM; Martínez CA; Politi PM; Rubio G; Alvarez AM
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-53-S15-56. PubMed ID: 9346223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel and carboplatin for advanced breast cancer.
    Perez EA; Hartmann LC
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):41-5. PubMed ID: 8893899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Taxol: initial Israeli experience with a novel anticancer agent.
    Sulkes A; Beller U; Peretz T; Shacter J; Hornreich G; McDaniel C; Winograd B
    Isr J Med Sci; 1994 Jan; 30(1):70-8. PubMed ID: 7908013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A phase II clinical study of China-made paclitaxel in the treatment of cancer patients].
    Wu H; Guan Z; Lin T
    Zhonghua Zhong Liu Za Zhi; 1998 Mar; 20(2):148-52. PubMed ID: 10920970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel (Taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines.
    Gianni L; Capri G; Munzone E; Straneo M
    Semin Oncol; 1994 Oct; 21(5 Suppl 8):29-33. PubMed ID: 7939759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.
    Lee FY; Borzilleri R; Fairchild CR; Kim SH; Long BH; Reventos-Suarez C; Vite GD; Rose WC; Kramer RA
    Clin Cancer Res; 2001 May; 7(5):1429-37. PubMed ID: 11350914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of the pharmacokinetics and safety of a paclitaxel injection NK and Taxol injection in breast cancer patients].
    Sagara Y; Rai Y; Sagara Y; Matsuyama Y; Baba S; Tamada S; Sagara Y; Ando M
    Gan To Kagaku Ryoho; 2009 Feb; 36(2):247-50. PubMed ID: 19223739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy.
    Mayerhofer K; Kucera E; Zeisler H; Speiser P; Reinthaller A; Sevelda P
    Gynecol Oncol; 1997 Jan; 64(1):109-13. PubMed ID: 8995557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials referral resource. Update on taxol trials.
    Cheson BD
    Oncology (Williston Park); 1993 Jan; 7(1):63, 66-7. PubMed ID: 8093592
    [No Abstract]   [Full Text] [Related]  

  • 18. Single-agent paclitaxel for the treatment of breast cancer: an overview.
    Hortobagyi GN; Holmes FA
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):4-9. PubMed ID: 8629036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Paclitaxel (taxol): a review of its antitumor activity and toxicity in clinical studies].
    Yamazaki S; Sekine I; Saijo N
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):605-15. PubMed ID: 9530372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial.
    Löffler TM; Freund W; Lipke J; Hausamen TU
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):32-4. PubMed ID: 9007118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.